Tofacitinib, which primarily inhibits JAK1 and JAK3 with partial JAK2 inhibition, is approved for conditions like rheumatoid arthritis (RA) and ulcerative colitis (UC), but has emerging applications in dermatologic diseases. The gene discussed is JAK1; the disease is ulcerative colitis.